Shire dodges HAE competition with $5.9B Dyax buyout

Dyax's ($DYAX) Phase III-ready prospect, DX-2930, would have competed directly with Shire's ($SHPG) Cinryze if and when it hit the market. But the Dublin drugmaker found a way to avoid the rivalry: a $5.9 billion buyout of the Massachusetts biotech. The deal will bolster the company's hereditary angioedema (HAE) franchise, which generates 15% of Shire's revenue and about 20% of earnings, Bernstein analyst Ronny Gal said in an investor note. More from FiercePharma

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

Gilead is working to move CAR-T med Yescarta into other types of NHL, and if data from an interim trial look-in are any indication, it's on its way.